Product Description
Standard :In-house Standards
AI Product Description
*The following content is generated by AI and is for reference only.
DM3, often referred to as Dimethyl 2,6-dimethyl-4-(dimethylamino)benzoate in specific chemical contexts or confused with the drug conjugate DM3 (a cytotoxic linker-payload), generally requires precise clarification. However, assuming the query refers to a common industrial solvent or intermediate sometimes abbreviated loosely as "DM3" in specific regional catalogs, such identification is highly ambiguous without further context. In pharmaceutical research, DM3 frequently denotes a specific maleimide-linker attached to a maytansinoid payload, known as Maytansine derivative M1, used in Antibody-Drug Conjugates (ADCs). Its molecular structure typically involves a complex arrangement including a maytansine core modified with a cleavable linker, rather than a simple small molecule with a single CAS number.
If referring to a generic chemical abbreviation like Dimethyl Phthalate (often confused), the CAS would differ significantly. For the ADC context, the DM3 payload is a potent microtubule inhibitor derived from maytansine. It binds to tubulin, preventing polymerization and arresting cell division in the G2/M phase, leading to apoptosis in rapidly dividing cancer cells. This makes it invaluable in targeted cancer therapies where an antibody delivers the toxic payload specifically to tumor antigens, sparing healthy tissue. The general formula for the maytansinoid core is C29H37N5O8, but the full DM3 conjugate varies based on the linker chemistry, making a universal molecular formula impossible to state without specifying the exact construct.
In industrial applications, if "DM3" refers to a specific plasticizer or solvent variant, it usually serves as a high-boiling point medium for coatings, inks, or synthetic rubber production, offering excellent solvency for resins and low volatility. Safety data indicates potential skin irritation and environmental toxicity, requiring careful handling protocols. Due to the ambiguity of the term "DM3" across different sectors—ranging from niche pharmaceutical linkers to obscure industrial codes—users must verify the specific chemical identity through supplier documentation or regulatory databases like PubChem before procurement. Accurate identification ensures compliance with safety regulations and optimal application performance in either therapeutic or manufacturing settings.